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Abstract
Rifampicin is an effective antibiotic against mycobacterial and other bacterial infections,
but resistance readily emerges in laboratory and clinical settings. We screened
Escherichia coli for rifampicin resistance and identified numerous mutations to the gene
encoding the β chain of RNA polymerase (rpoB), including an unusual nine nucleotide
deletion mutation. Structural modeling of the deletion mutant indicates locations of
potential steric clashes with rifampicin. Sequence conservation in the region near the
deletion mutation suggests a similar mutation may also confer resistance during the
treatment of tuberculosis.
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Introduction
Rifampicin (RIF) is a member of rifamycin antibiotics used in the treatment of
tuberculosis and other bacterial infections [Sensi, 1983]. It targets bacterial RNA
polymerases by binding near the polymerase active site and inhibiting the elongation of
nascent mRNA [Campbell et al., 2001]. The catalytic core of bacterial RNA polymerases
consists of α2, β, β´, and ω chains, and rifampicin binds to a pocket formed by the β chain
(Fig. 1A) [Campbell et al., 2001; Molodtsov et al., 2013]. Although rifampicin binds in
the RNA tract, many of the residues in the rifampicin binding pocket do not directly
contact the RNA. Numerous mutations in the RNA polymerase β chain confer rifampicin
resistance (RIFR) in Escherichia coli and Mycobacterium tuberculosis [Xu et al., 2005;
Makiela-Dzbenska et al., 2011; Zhou et al., 2013; Jin, and Gross, 1989; Sandgren et al.,
2009; Barrick et al., 2010]. These mutations are clustered in four regions of RNA
polymerase β, termed RIF resistance-determining regions (RRDRs) N, I, II, and III
(Molodtsov et al. 2016). Crystal structures of rifampicin bound to RNA polymerases of
Thermus aquaticus and E. coli show that all four RRDRs consist of residues located
within ~10 Å of rifampicin [Campbell et al., 2001; Molodtsov et al., 2013]. RIFR
mutations and structural studies have provided detailed information on how M.
tuberculosis and other bacteria evade the antibiotic action of rifampicin and other
rifamycins [Artsimovitch et al., 2005; Molodtsov et al., 2017].
In this study, we selected E. coli for rifampicin resistance in the absence of
mutagens and sequenced a region of RNA polymerase β chain encompassing RRDRs I,
II, and III to identify new RIFR mutations. Nonpathogenic E. coli serves as an excellent
experimental system to probe rifampicin resistance because of its ease of handling in the
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laboratory in contrast to M. tuberculosis, and there exists an abundance of structural and
biochemical information on its RNA polymerase [Molodtsov et al., 2013; Campbell et al.,
2001; Kang et al., 2017; Gill, and Garcia, 2011]. While most of the E. coli mutants
contained previously characterized mutations, we identified a new mutation located in
RRDR-I, an unusual in-frame deletion that did not result in misfolding of RNA
polymerase.

Results & Discussion
Rifampicin resistance in E. coli. Selection of E. coli K-12 MG1655 laboratory strain
bacteria on LB plates containing rifampicin readily produced a large and variable number
of rifampicin-resistant clones (results not shown). The number of RIFR colonies and the
total live bacteria in each of 64 cultures were counted and used to compute the mutation
rate from Luria-Delbrück fluctuation tests [Luria, and Delbrück, 1943; Gillet-Markowska
et al., 2015; Ycart, and Veziris, 2014]. We estimate the mutation rate of the MG1655
strain at 2.0 x 10-9, which is in general agreement with other studies on E. coli lab strains
and rifampicin-resistance [Bjedov et al., 2003; Galán et al., 2007] but lower than rates
from clinical isolates [Baquero et al., 2004].
Identity of RIF-resistance mutations. The chromosomal rpoB gene fragment containing
the region that codes for residues 473-720 of the β chain of RNA polymerase was directly
amplified from RIFR colonies using the polymerase chain reaction, resulting in a 744 base
pair band (results not shown). This section of E. coli RNA polymerase encompasses the
rifampicin-binding site and RIF resistance-determining region, including clusters I
(residues 507-533), II (residues 563-572), and III (residue 687), but not the N-terminal
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cluster (residue 146). Sequencing of PCR products revealed 16 different mutations in
clusters I and II (Table 1). All but one of the cluster I mutations have previously been
reported in rifampicin-resistant E. coli mutants. The 9 bp deletion had not been
previously reported, to our knowledge, but is similar to a previously characterized
deletion that replaces 507-GSSQL-511 with V [Jin, and Gross, 1989]. The deleted
sequence (nucleotides 1517-1525 in the rpoB open reading frame, TCGGTTCCA)
contained no obviously unusual features (e.g. A-T rich, long tracts of single nucleotides,
self-annealing sequences). Mutations at I572 and S574 in cluster II have also previously
been identified in RIF-resistant E. coli clones [Jin, and Gross, 1989; Zhou et al., 2013;
Makiela-Dzbenska et al., 2011; Sandgren et al., 2009; Barrick et al., 2010]. Several of
these mutations occurred in positions that increased transcript deletions (Q513) or
decreased transcriptional elongation slippage (D516 and I572) by E. coli RNA
polymerase [Zhou et al., 2013].
Two of the clones (out of 81 total) contained no mutations to the coding region
for residues 473-720. It is possible that these contained a mutation to the N-terminal
cluster of rpoB or other regions of genes encoding RNA polymerase. Alternatively,
mutations of other E. coli genes could lead to rifampicin secretion or breakdown could
also result in resistance. We did not subject these clones to genome sequencing to
determine if this was the case. Of the sequenced clones, the H526Y mutant was the most
abundant (29/81). The mutations of nucleotides 1546 (GAC to AAC; D516N), 1547
(GAC to GGC; D516G), 1576 (CAC to TAC; H526Y), and 1592 (TCC to TTC; S531F),
were the only transition mutations observed (35/81).
Relationship of mutations to the rifampicin binding site in RNA polymerase.
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Rifampicin-resistant mutants were mostly clustered to the rifampicin binding site in RNA
polymerase β (Fig. 1B). Several of the residues where mutations occur are adjacent to
where rifampicin binds (Q513, D516, H526, S531, I572). Mutations to these first shell
residues are expected to alter the shape and/or chemical characteristics of the rifampicin
binding site without substantially affecting the structure or function of RNA polymerase.
According to the RNA polymerase-rifampicin complex structure [Molodtsov et al.,
2013], the serine 512 and 574 side chains do not contact rifampicin, but point towards the
interior of the protein. Mutation to a larger tyrosine at residue S512 or at S574 would
require a change to the backbone structure, leading to possible changes in the rifampicin
binding surface.
Unusual in-frame deletion near rifampicin binding site.
The deletion of nine base pairs (1517-1525; Δ9) from the rpoB gene changes 506-FGSS509 to C506. Because RNA polymerase is essential to the survival and growth of E. coli,
we concluded that the Δ9 mutation did not create a non-functional protein and that the
folding and structure of the enzyme was largely retained. In wild-type RNA polymerase,
residues 506-509 reside at the end of an α-helix adjacent to the rifampicin binding site
(Fig. 1B and 2A). However, none of the residues contact rifampicin in the crystal
structure.
To understand the impact of the three-residue deletion on the structure of RNA
polymerase, the translated protein sequence from the Δ9 mutant of rpoB was threaded
into known crystal structures of E. coli RNA polymerase using Iterative Threading
ASSEmbly Refinement (I-TASSER; [Yang et al., 2015]). The Δ9 mutant model with the
highest confidence score (C-Score of 1.65) produced by I-TASSER was highly similar to
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known E. coli RNA polymerase crystal structures with identical secondary structural
elements and a similar rifampicin binding site (Fig. 2A). The 506-FGSS-509 sequence
lies at the C-terminal end of an α helix pointing to where rifampicin binds, with glycine
507 marking the end of the helix and the start of a loop. The threaded model generated
by I-TASSER indicates that shortening of the β chain sequence by three residues leads to
the truncation of the α helix by one turn, but no substantial changes to the rest of the
protein backbone. A comparison of the RNA polymerase-rifampicin complex crystal
structure (4KMU; [Molodtsov et al., 2013]) with the E. coli RNA polymerase elongation
complex cryo-electron microscopy structure (5UPC; [Kang et al., 2017]) indicates that
rifampicin inhibits RNA synthesis by blocking the path of the nascent RNA chain
[McClure, and Cech, 1978; Campbell et al., 2001; Lin et al., 2017] and that residues 506509 of the β-chain lie near where the backbone of the transcript and template strand
would lie in the transcriptional elongation complex (Fig. 2B). The side chain of Q510
(wild type numbering) in the Δ9 mutant makes contact with the RNA transcript backbone
(Fig. 2B), but the clash could be alleviated by a rotamer change. The observation that Δ9
rpoB mutant formed a colony suggests that RNA polymerase activity is not substantially
decreased by the unusual mutation.
Although the Δ9 mutant does not result in large structural rearrangements near the
mutation site, the sequence change does lead to rifampicin resistance. The backbone of
the next five residues after Δ9 mutation (QLSQF, numbered residues 510-514 in the wild
type sequence) follows closely to the structure of full length, wild-type rpoB (Fig. 2C),
but subtle structural changes in the Δ9 mutant model lead to steric clashes with
rifampicin, particularly at Q513, F514, and I572 (wild type numbering). The strong
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overlap between rifampicin atoms and the Δ9 mutant model denoted by red disks in
Figure 2C suggest that rifampicin may not bind well to the mutant without alterations to
the protein surface. One such change could be the rotations of side chains away from
rifampicin if there is space. The clashes between rifampicin and F514 and I572 can be
resolved by rotamer changes in the two side chains. However, the model indicates that
the side chain of Q513 forms hydrogen bonds with the Q510 backbone and H526 side
chains. We note that the hydrogen bond between Q510-Q513 in the Δ9 mutant model is
not present in wild type crystal structures (4KMU.pdb and 5UPC.pdb). This interaction
could prevent the Q513 side chain from swinging out of the way of rifampicin. Without
an experimental atomic structure of this Δ9 mutant of RNA polymerase, we cannot be
sure how this mutation confers rifampicin resistance, but we speculate that the subtle
changes in structure immediately after residue 506, specifically the formation of a new
backbone-side chain hydrogen bond, lock the β-chain into a conformation that has a
lower binding affinity to rifampicin, thereby conferring resistance.
Implications for rifampicin resistance in M. tuberculosis and other bacteria.
Rifampicin resistance is a major problem for treatment of human infections by
Staphyloccocus aureus and M. tuberculosis. Many rifampicin-resistant clinical isolates
of Staphyloccocus contain nonsynonymous single nucleotide substitutions that result
amino acid substitutions in the rifampicin binding site (e.g. S455A, L466S, H481N)
[Zhou et al., 2012; Murugan et al., 2015; Hellmark et al., 2009], but a three-nucleotide
insertion mutant of rpoB has also been isolated [Hellmark et al., 2009]. A ninenucleotide deletion similar to the Δ9 mutant identified in our study may also generate a
RIFR mutant, as the RNA polymerase β amino acid sequence corresponding to 506-
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FGSS-509 in E. coli is the same in S. aureus (Table 2). A comparison of crystal
structures of rifampicin bound to RNA polymerases of M. tuberculosis (MtrpoB) and E.
coli (EcrpoB) indicates that rifampicin binds to highly conserved sites with nearly
identical structures in both enzymes [Lin et al., 2017]. The most clinically important
mutation in the treatment of tuberculosis, serine 450 (or 531 in E. coli) to leucine
[Williams et al., 1998; Telenti et al., 1993], was not observed in our screen due to the
codon encoding serine (TCT) requiring two mutations to mutate the residue to leucine.
We did observe a similar S531F mutant, which required only a single mutation (TCC to
TTC). The Δ9 rifampicin resistant mutant in E. coli converts 506-FGSS-509 to C506.
Homologous residues in RNA polymerase β chains of 10 other bacteria are almost
identical to E. coli RNA polymerase (Table 2). A similar nine nucleotide deletion in
MtrpoB would change the corresponding sequence to 425-SQLSQF-428 instead of
CQLSQF in EcrpoB. Serine and cysteine differ only by one atom (oxygen replaced by
sulfur) and are chemically similar. Thus, we hypothesize that a similar nine nucleotide
deletion mutation may also confer resistance in M. tuberculosis and other bacteria.

Materials and Methods
Selection of RIFR strains of Escherichia coli. E. coli K-12 MG1655 was streaked on
Luria-Bertani Broth (LB)-agar plates to yield single colonies. Colonies were picked and
dissolved in 200 µl sterile saline. 10 µl of bacteria were diluted to individual cultures of
25 ml of LB and shaken overnight at 37°C. 200 µl of each bacterial culture was plated on
LB-agar plates containing 100 µg/mL rifampicin and cultured at 37°C overnight. Plates
generally contained between 5 and 250 colonies. In addition, each individual 25 mL
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culture was serially diluted to 10-5 or 10-6 and plated on LB-agar plates without
antibiotics to determine the concentration of live bacteria in the culture.
Sequencing of E. coli rpoB gene fragments form RifR strains. Colonies were restreaked
onto LB+rifampicin plates to obtain freshly grown bacteria. Single colonies were picked
and dissolved in 1X GoTaq Green Master Mix (Promega Corporation, Madison,
Wisconsin) with 1 µM rpoBforward (5´- CGT GCG GTG AAA GAG CGT CTG TCT 3´) and rpoBreverse (5´- ACG TTT AGC TAC CGC AGT TAC ACC -3´) primers. The
primers are designed to amplify nucleotides 1417-2160 of the E. coli K-12 MG1655 rpoB
open reading frame. The rpoB fragment was amplified directly from colonies with 30
cycles of 95°C for 30 seconds, 57°C for 45 seconds, and 72°C for 1 minute after initial
denaturation at 95°C for 2 minutes. Polymerase chain reaction (PCR) amplification was
confirmed by agarose gel electrophoresis. PCR products were purified using the
MinElute PCR Purification Kit (Qiagen Sciences, Germantown, Maryland) and
sequenced by Sanger DNA sequencing using the rpoBforward primer (Genewiz, Inc.,
South Plainfield, New Jersey).
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Table 1. Mutations to rpoB gene identified from rifampicin-resistant E. coli.
Residue number Protein sequence Mutation*
Number of
change
observed clones
506-509

FGSS to C

9 bp (1517-1525)
1
deletion
512
S to Y
TCT to TAT (1534)
1
513
Q to K
CAG to AAG (1537) 2
Q to L
CAG to CTG (1538) 4
Q to P
CAG to CCG (1538) 1
516
D to Y
GAC to TAC (1546) 3
D to N
GAC to AAC (1546) 1
D to V
GAC to GTC (1547) 11
D to G
GAC to GGC (1547) 2
526
H to Y
CAC to TAC (1576) 29
H to N
CAC to AAC (1576) 8
H to D
CAC to GAC (1576) 1
H to L
CAC to CTC (1577) 4
531
S to F
TCC to TTC (1592)
3
572
I to F
ATC to TTC (1714)
6
I to L
ATC to CTC (1714) 1
574
S to Y
TCT to TAT (1721)
1
* Nucleotide number in E. coli rpoB open reading frame in parentheses.
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Table 2. Protein sequence alignment of several bacterial RNA polymerases in RRDR I &
II.
Bacterial species

rpoB residue

RDRR I and II Protein sequence†

Escherichia coli
Pseudomonas aeruginosa
Neisseria meningitidis
Clostridioides difficile
Streptococcus pneumoniae
Staphylococcus aureus
Mycobacterium tuberculosis
Mycobacterium smegmatis
Chlamydia pneumoniae
Thermus thermophilus
Thermus aquaticus
Sequence conservation‡
Mutations in this study

505-533, 571-575
508-538, 574-578
527-557, 598-602
479-509, 548-552
475-505, 544-548
459-488, 525-529
422-452, 490-494
419-449, 487-491
448-478, 516-519
383-413, 451-455
383-413, 451-455

FFGSSQLSQFMDQNNPLSEITHKRRISAL
FFGSSQLSQFMDQNNPLSEITHKRRVSAL
FFGSSQLSQFMDQTNPLSEVTHKRRVSAL
FFGSSQLSQFMDQTNPLSELTHKRRLSAL
FFGSSQLSQFMDQHNPLSELSHKRRLSAL
FFGSSQLSQFMDQANPLAELTHKRRLSAL
FFGTSQLSQFMDQNNPLSGLTHKRRLSAL
FFGTSQLSQFMDQNNPLSGLTHKRRLSAL
FFGRSQLSQFMDQTNPVAELTHKRRLSAL
FFSRSQLSQFKDETNPLSSLRHKRRISAL
FFSRSQLSQFKDETNPLSSLRHKRRISAL
**: ****** * **: : ****:***
---- ^^ ^
^
^

† Protein sequence shown in one-letter code. Sequence corresponding with the ∆9 deletion mutation is
shown in bold and denoted by dashes in the last row. Point mutations observed in this study are denoted by
^ in the last row.
‡ Complete sequence identity amongst the RPOB sequences represented here denoted by “*”; Conservation
of amino acid type (positively or negatively charged, hydrophobic, hydrophilic, side chain size) denoted by
“:”.
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LINSL
LINSL
LINSL
LINSL
LINNL
LINSL
LIGSL
LIGSL
LITSL
LITSL
LITSL
** **
^ ^

A

B

Figure 1. Rifampicin binding to the bacterial transcriptional machinery. (A) Rifampicin
(yellow spheres) binds inside the DNA-RNA tunnel of RNA polymerase elongation
complex (gray surface representation; 5UPC.pdb) to the surface of the β chain (cyan).
The rifampicin binding site overlaps with the path of the nascent RNA chain (green).
The template (red) and non-template (orange) DNA backbones are shown as lines, and
the polymerase active site is shown as a magenta sphere. (B) The rifampicin (Sticks
representation; yellow carbons, blue nitrogens, red oxygens, white hydrogens) binding
site (black box in (A)) and its solvent-exposed surface (gray) in E. coli RNA polymerase
β chain (cyan) from 4KMU.pdb. Locations of mutations identified in this study are
depicted as magenta lines and labeled.
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A

B

C

Figure 2. The structure of the I-TASSER model of the Δ9 mutant. (A) The Δ9 mutant
model protein backbone (green lines connecting α-carbons) is superimposed on the
crystal structure of rifampicin (pink lines) bound to the wild type E. coli RNA
polymerase β chain (4KMU.pdb; gray ribbon). Rifampicin is show in yellow sticks. The
red oval highlights the location of 506-FGSS-509 in the wild type RNA polymerase,
which is mutated to C506 in the Δ9 mutant. (B) The Δ9 mutant (green lines connecting αcarbons) is superimposed on the crystal structure of a DNA (blue)-RNA (brown) hybrid
bound to the E. coli RNA polymerase transcriptional elongation complex (5UPC.pdb;
pink lines). Residues 500-514 of the Δ9 mutant model are show in sticks. (C)
Superimposition of rifampicin (sticks with yellow carbons) onto the Δ9 mutant model
indicates steric clashes (red disks) with Q513, F514, and I572 (highlighted in red ovals).
The side chain of Q513 forms a hydrogen bond (yellow dotted line) with the backbone
carbonyl of Q510 (wild type numbering). Figure 1B, 2A, 2B, and 2C are viewed in the
same orientation. Figures and clashes were generated in PyMol [DeLano, 2014].
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